-- Director and Co-founder Mitchell Finer, Ph.D. to Retire for New Industry Role -- -- President, CSO Mehdi Gasmi, Ph.D. to Transition to Board of Directors -- -- Adverum Continues to Build Senior Team with Deep Functional Expertise with Three New Vice Presidents --...

MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular diseases, today announced that it will host a conference call and audio webcast on...

Carol Hoang, Pharm.D, MBA Joins as Vice President, Medical Affairs and James Shahbazian Joins as Vice President, Finance MENLO PARK, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company...

-- OPTIC Phase 1 Data for ADVM-022 in Wet AMD for First Cohort to be Presented at Retina Society Annual Meeting in September 2019 -- MENLO PARK, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy...

-- Continued Progress in the OPTIC Phase 1 Clinical Trial -- Patients Receiving Single Intravitreal Injection of ADVM-022 Dosed at 2 x 10^11 vg/eye MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage...

FDA Lifts Clinical Hold on Second Cohort to Allow Dose Escalation Robust Preliminary Anatomical Response from First Cohort Leads Adverum to Begin Dosing Second Cohort at Lower Dose MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc....

MENLO PARK, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the first quarter ended March 31,...

Independent Directors Rekha Hemrajani, James Scopa and Mark Lupher Added to the Board Patrick Machado Appointed as Board Chair; Paul Cleveland Retires from the Board MENLO PARK, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a...

- Oral Presentation Today at 10:45 am ET at the ASGCT 22nd Annual Meeting - - ADVM-022 Was Demonstrated to be Safe and Well Tolerated, Provided Long-term, Sustained Aflibercept Expression out to 30 Months Following a Single Intravitreal Injection - - Long-term...

-- ADVM-022 Safely Administered Sequentially to the Second Eye in Preclinical Study -- MENLO PARK, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular...